MAPK
Les MAPK sont une famille de kinases protéiques impliquées dans une variété de processus cellulaires, y compris la croissance, la prolifération, la différenciation et les réponses au stress. La voie de signalisation MAPK comprend plusieurs niveaux, y compris ERK, JNK et p38 MAPK, chacun jouant des rôles distincts dans la fonction cellulaire. La dérégulation de la signalisation MAPK est liée au cancer, aux maladies inflammatoires et aux troubles métaboliques. Chez CymitQuimica, nous offrons un large éventail d'inhibiteurs et d'activateurs de MAPK pour soutenir vos recherches en biologie cellulaire, transduction de signaux et mécanismes des maladies.
886 produits trouvés pour "MAPK"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
LC 2 Epimer
CAS :<p>Negative control for LC 2.</p>Formule :C59H71ClFN11O7SCouleur et forme :SolidMasse moléculaire :1132.8YN14
<p>YN14 is a highly potent and selective KRASG12C proteolysis targeting chimera (PROTAC) capable of forming a stable KRASG12C: YN14: VHL ternary complex with low</p>Degré de pureté :98%Couleur et forme :Odour SolidCC-401
CAS :<p>CC-401 is a specific inhibitor of JNK (Ki: 25-50nM).</p>Formule :C22H24N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :388.47Murrayafoline A
CAS :<p>Murrayafoline A is a useful organic compound for research related to life sciences. The catalog number is T124835 and the CAS number is 4532-33-6.</p>Formule :C14H13NOCouleur et forme :SolidMasse moléculaire :211.264Rineterkib hydrochloride
CAS :<p>Rineterkib hydrochloride (B) is an oral RAF/ERK1/2 inhibitor for MAPK-driven cancers, including KRAS/BRAF-mutant NSCLC and CRC.</p>Formule :C26H28BrClF3N5O2Couleur et forme :SolidMasse moléculaire :614.89Pan-RAS-IN-7
CAS :<p>Pan-RAS-IN-7 (Compound D101) is a broad-spectrum RAS inhibitor used in the synthesis of antibody-drug conjugates (ADCs). It is also applicable in cancer research.</p>Formule :C59H76N8O8Couleur et forme :SolidMasse moléculaire :1025.28MAPK Inhibitor Library
<p>A unique collection of 365 compounds targeting MAPK signaling for drug discovery in MAPK related diseases;</p>Couleur et forme :Odour SolidPROTAC SOS1 degrader-1
CAS :<p>PROTAC SOS1 degrader-1: potent, DC50 98.4 nM, inhibits KRAS mutant cancer cells, low-toxic antitumor.</p>Formule :C57H76O4ClFN10SCouleur et forme :SoildMasse moléculaire :1050.54443KRASG12C IN-14
<p>KRASG12C IN-14 (compound 15), a potent inhibitor specifically designed for the KRAS G12C mutation, exhibits impressive efficacy in impeding CYPA-dependent KRAS-BRAF interaction and ERK phosphorylation in NCI-H358 cells, both with an IC 50 of 0.002 μM.</p>Formule :C51H65F4N9O9S2Couleur et forme :SolidMasse moléculaire :1088.24HPK1-IN-39
<p>HPK1-IN-39 (Compound 10n), a selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) with an inhibitory concentration (IC50) of 29 nM, impedes the</p>Formule :C26H27N7O2Couleur et forme :SolidMasse moléculaire :469.54NUCC-0200808
<p>NUCC-0200808 (Compound 12g) is an MNK1 inhibitor with an IC50 of 42 nM. It reduces eIF4E phosphorylation and cell viability in AML cells and induces apoptosis. NUCC-0200808 shows potential for research in the field of leukemia.</p>Couleur et forme :Odour SolidMRTF-A-IN-2
<p>MRTF-A-IN-2 (compound 16) is an inhibitor of MRTF-A. It effectively suppresses cell proliferation and induces senescence in HCC cells.</p>Couleur et forme :Odour SolidSS47
CAS :<p>SS47 is a PROTAC that degrades immunosuppressive HPK1 via proteasome; boosts BCMA CAR-T cell cancer therapy.</p>Formule :C49H56N6O12SCouleur et forme :SolidMasse moléculaire :953.07BAS 00489700
CAS :<p>BAS 00489700 is a N-UTR interaction inhibitor. BAS 00489700 inhibits virus replication in cell culture.</p>Formule :C19H16N2O4Degré de pureté :99.78%Couleur et forme :SolidMasse moléculaire :336.34KRAS G12D inhibitor 7
CAS :<p>KRAS G12D inhibitor 7, is a highly potent inhibitor specifically targeting KRAS G12D.</p>Formule :C32H38N8O3Couleur et forme :SolidMasse moléculaire :582.709(S)-BAY-293
CAS :<p>(S)-BAY-293 is a potent pan-KRAS inhibitor for the study of primary non-small lung and pancreatic cancers.</p>Formule :C25H28N4O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :448.58PDE4-IN-26
<p>PDE4-IN-26 (Compound A5) is an orally active, highly selective inhibitor of PDE4. It exhibits anti-inflammatory properties by inhibiting p38 MAPK phosphorylation. In mouse models of acute lung injury and chronic obstructive pulmonary disease, PDE4-IN-26 reduces lung inflammation, damage, and fibrosis, while promoting sputum secretion and alleviating cough. It is useful for researching lung injury-related diseases.</p>Formule :C22H18F2N4O3SCouleur et forme :SolidMasse moléculaire :456.47LYMTAC-2
<p>LYMTAC-2 is a lysosome-targeting chimera (LYMTAC) developed to degrade membrane-associated proteins through lysosomal membrane proteins (LMP) such as RNF152, LAPTM4a, and LAPTM5. It forms a ternary complex with target proteins like KRASG12D, facilitating their relocation to lysosomes and resulting in ubiquitin-dependent degradation. This compound has potential for studying membrane protein regulation and devising strategies to counter resistance in KRAS-driven signaling pathways.</p>Couleur et forme :SolidMasse moléculaire :1248.44Mitogen-activated protein kinase 1
CAS :<p>Mitogen-activated protein kinase 1 (MAPK1) activates the p38/NF-κB pathway and regulates cellular processes in sepsis-associated diseases.</p>Degré de pureté :98%Couleur et forme :SolidJNK3 inhibitor-7
<p>Potent, oral JNK3 inhibitor-7 crosses blood-brain barrier, IC50: 53 nM (JNK3), offers neuroprotection, potential in AD research.</p>Formule :C32H31N7O3Couleur et forme :SolidMasse moléculaire :561.63
